Who wants Optimer Pharmaceuticals and its high-powered antibiotics? A handful of drugmakers, apparently.
A year after HemCon Medical Technologies filed for Chapter 11 reorganization following the loss of a patent fight, the Oregon maker of gels and dressings has been sold.
As its net profits careen into the red, Theragenics is considering a buyout offer worth up to $71.4 million from private equity outfit Juniper.
While Valeant Pharmaceuticals was chatting up Actavis about a potential merger-of-equals, Actavis was apparently mulling a bid for Warner Chilcott, the Irish drugmaker that specializes in women's health and dermatology.
Instem has bought a ticket to play a larger role in the market for early-stage clinical trials. The provider of IT solutions has acquired Logos Technologies, which provides electronic data-capture (EDC) software for pharma, biotech and CRO companies.
Swiss cardiac stent maker Biosensors International will pay at least $51 million for U.S.-based Spectrum Dynamics, a developer of high-definition medical imaging technology.
Pfizer's spinoff of its animal health business into Zoetis is the biggest IPO this year. And the spinoff that created the newest Big Pharma company, AbbVie, was no slouch.
The China drug market is getting trickier but that is not stopping the big names of biotech and pharma from plowing ahead with tie-ups of various kinds to sell into the enormous market. Amgen today said it is ready to attack the Chinese market with one of its cancer drugs.
As Sony works to build its presence in the medical device world, the Japanese giant is investing $10 million in Rainbow Medical, an Israeli incubator with portfolio companies that make stents, stimulators and other devices.
ICU Medical is considering selling itself, retaining advisers to find suitors and weigh offers that may soar past $1 billion.